Discounted Cash Flow (DCF) Analysis Levered

BioVie Inc. (BIVI)

$0.6463

-0.06 (-8.37%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
2028
Projected
Revenue ----------
Revenue (%)
Operating Cash Flow ----------
Operating Cash Flow (%)
Capital Expenditure ----------
Capital Expenditure (%)
Free Cash Flow ----------

Weighted Average Cost Of Capital

Share price $ 0.6,463
Beta 1.335
Diluted Shares Outstanding 32.48
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 29.82%
Risk-Free Rate
Market Risk Premium
Cost of Equity 10.657
Total Debt 14.42
Total Equity 20.99
Total Capital 35.41
Debt Weighting 40.72
Equity Weighting 59.28
Wacc

Build Up Free Cash Flow

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
2028
Projected
Revenue ----------
Operating Cash Flow ----------
Capital Expenditure ----------
Free Cash Flow ----------
WACC
PV LFCF ----------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 18.46
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -5.04
Equity Value -
Shares Outstanding 32.48
Equity Value Per Share -